Genital herpes

Rational Vaccines Herpes Simplex Type 2 (HSV-2) Therapeutic Vaccine Candidate Demonstrates Efficacy in a Therapeutic Animal Study

Retrieved on: 
Friday, July 8, 2022
Diagnosis, Mouse, Fever, Blister, Patient, School, Biotechnology, Nerve agent, Fissure, Severe cognitive impairment, UC Davis School of Veterinary Medicine, Disease, Louisiana State University, Chills, Erythema, Infection, Company, National, LSU, Simplex, Ulcer, Veterinary medicine, Virology, Guinea, NIH, World, WHO, Western world, Genital herpes, World Health Organization, Myalgia, Virus, Human, Animal, Neonatal infection, Vaccine, Foundation for the National Institutes of Health, HSV-2, HSV, Pharmaceutical industry

WOBURN, Mass. and OXFORD, England, July 8, 2022 /PRNewswire/ -- Rational Vaccines, a company focused on revolutionizing the treatment and prevention of herpes to eradicate the disease, today announced findings from an National Institutes of Health (NIH)-funded pilot study of RVX201, the Company's lead therapeutic vaccine candidate for herpes simplex virus type 2 (HSV-2). Results showed that treatment with RVX201 led to a reduction in recurrent genital lesions when compared to gD2-alum/MPL vaccine or placebo in vivo. In addition, RVX201 appears to generate a robust cellular immune response equivalent to that elicited by wild-type HSV-2 on Day 7 post-infection. Results showed that in comparison to no vaccine, animals that received RVX201 had the number of symptomatic days reduced by 45 percent while those that received gD2-alum/MPL vaccine only had a 24 percent reduction in symptomatic days.

Key Points: 
  • and OXFORD, England, July 8, 2022 /PRNewswire/ -- Rational Vaccines, a company focused on revolutionizing the treatment and prevention of herpes to eradicate the disease, today announced findings from an National Institutes of Health (NIH)-funded pilot study of RVX201, the Company's lead therapeutic vaccine candidate for herpes simplex virus type 2 (HSV-2).
  • Results showed that treatment with RVX201 led to a reduction in recurrent genital lesions when compared to gD2-alum/MPL vaccine or placebo in vivo.
  • The herpes simplex virus (HSV), commonly referred to as herpes, is categorized into two types: herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2).
  • Rational Vaccines is revolutionizing the treatment, prevention, and diagnosis of herpes and herpes-related diseases with its rationally engineered, live-attenuated viral immunotherapeutic and prophylactic vaccine candidates.

Genital Herpes Drugs Development Research Report 2022: Descriptive Licensing and Collaboration Details, R&D Brief, MoA & Developmental Activities - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 23, 2022
Health, Pharmaceutical, Molecule, Discovery, R, Genital herpes, Therapy, Decision-making, Health care, Mall of America, Infection, Research, Company, Medication, News, SEC, History, Target, Pharmaceutical industry, Surveying, Marketing

The "Genital Herpes Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Genital Herpes Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to ResearchAndMarkets.com's offering.
  • The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
  • The Genital Herpes (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Genital Herpes and features dormant and discontinued projects.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

Genital Herpes Pipeline Insight Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Monday, May 30, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Herpes simplex virus, DNA, II, Infection, News, Sex organ, HSV, Mergers and acquisitions, Clinical trial, Half-life, Cell, Virus, Therapy, Genital herpes, Discovery, Plasma protein binding, Pritelivir, Immunoglobulin G, Pharmaceutical industry, Vaccine, Beef cattle

The "Genital Herpes - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Genital Herpes - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This "Genital Herpes- Pipeline Insight, 2022" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Genital Herpes pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Genital Herpes R&D.
  • This segment of the report provides insights about the different Genital Herpes drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.

STDcheck.com Data Reveals Genital Herpes Rate Rose Average Of 56% In Super Bowl-Hosted Cities Last 3 Years

Retrieved on: 
Wednesday, May 25, 2022
Education, PayPal, Research, Flexible spending account, Gonorrhea, Flexible, Currency strap, 2021–22 NCAA football bowl games, STD, Multimedia, Health, Chlamydia, HSAS, Hepatitis B, Hepatitis C, Privacy, Syphilis, Hepatitis A, Industry, Medical director, Partnership, Genital herpes, Travel, HIV, Super Bowl, Health savings account, NFL, Birth control

Research from STDcheck.com reveals that genital herpes rose an average of 56% year-over-year in the metro areas that hosted the NFL's biggest game the last three years.

Key Points: 
  • Research from STDcheck.com reveals that genital herpes rose an average of 56% year-over-year in the metro areas that hosted the NFL's biggest game the last three years.
  • The last three Super Bowls were held in Miami, Florida in 2020; Tampa, Florida in 2021; and Los Angeles, California in 2022.
  • Data shows that after Miami hosted the Super Bowl in 2020, the genital herpes rate rose by an astounding 101.54% year-over-year.
  • This past year in Los Angeles, the genital herpes rate rose 16.82% year-over-year.

STDcheck.com Confirms New Orleans as U.S. City with Highest Prevalence of Genital Herpes

Retrieved on: 
Thursday, May 5, 2022
Laboratory, Privacy, Hepatitis C, Hepatitis B, LabCorp, Genital herpes, Simplex, Blog, HSAS, Health, Prevalence, PayPal, Partnership, Syphilis, HIV, Diagnosis, Chlamydia, Industry, STD, Flexible spending account, Hepatitis A, Gonorrhea, Disease, Education, Medical director, Quest Diagnostics, Flexible, Health savings account, Currency strap, Multimedia, Birth control, Medical device, Online shopping

HOUSTON, May 5, 2022 /PRNewswire/ -- STDcheck.com, which has provided fast, private and affordable STD tests to more than 2 million people since 2010, today announced that New Orleans is the U.S. city with the highest prevalence of genital herpes.

Key Points: 
  • Through partnerships with various nonprofits and educational institutes, STDcheck.com tested over 130,000 people for genital herpes last year.
  • This makes New Orleans the highest in the nation for genital herpes diagnosis.
  • "New Orleans could be on the precipice of having a public health crisis due to the high spread of genital herpes in the city.
  • In addition, theprevalence rate of New Orleans drastically increased 57% over the last three years, from just 13.1% in 2019.

Advisory - Apotex recalls Apo-Acyclovir tablets due to a nitrosamine impurity

Retrieved on: 
Thursday, April 28, 2022
Shingles, Drinking water, Vegetable, Canada, Pharmacy, Tablet, Patient, Genital herpes, Health Canada, Cancer, Ciba-Geigy Canada Ltd v Apotex Inc, Aciclovir, NDMA, Dairy, Nitrosamine, Recurrence, Risk, Air pollution, Health, Dietary supplement

Issue:Certain lots are being recalled due to the presence of a nitrosamine impurity above the acceptable level.

Key Points: 
  • Issue:Certain lots are being recalled due to the presence of a nitrosamine impurity above the acceptable level.
  • Apotex Inc. is recalling certain lots of Apo-Acyclovir (acyclovir) tablets, in 200 mg and 800 mg strengths, due to the presence of a nitrosamine impurity (N-nitrosodimethylamine [NDMA]) above the acceptable level.
  • There is no immediate risk in continuing to take the recalled medication, since the increased risk of cancer typically involves long-term exposure to the nitrosamine impurity above the acceptable level.
  • Should any additional recalls be deemed necessary, Health Canada will update the table and inform Canadians.

Rational Vaccines' RVX1001 Vaccine Candidate Protects Against HSV Ocular Infection in vivo

Retrieved on: 
Tuesday, December 28, 2021
People, Antibody, Fissure, Company, World, Louisiana State University, Blister, Immune system, School, Fever, Department, VC2, WHO, Infection, HK, Herpes simplex keratitis, LSU, Vaccination, Myalgia, Vaccine, Virology, UC Davis School of Veterinary Medicine, Patient, Severe cognitive impairment, McQuillan, LSU School of Music, HSV-1, Alzheimer's disease, HSV-2, HSV, Mouse, Research, Prevalence, Virus, Veterinary medicine, Diagnosis, Cornea, Frontiers, Keratitis, Neutrophil, Chills, Genital herpes, Multimedia, Erythema, Dementia, Disease, Social stigma, Biotechnology, MRCVS, World Health Organization, BVM, Doctor of Philosophy, Simplex, Ulcer, Immunology

Dr. Kousoulas stated, "These data provide in vivo proof of concept for the prophylactic treatment of herpetic keratitis with our HSV-1 vaccine.

Key Points: 
  • Dr. Kousoulas stated, "These data provide in vivo proof of concept for the prophylactic treatment of herpetic keratitis with our HSV-1 vaccine.
  • Results showed that RVX1001 administered prophylactically protected mice against lethal ocular HSV-1 challenge and the development of herpetic keratitis.
  • Herpetic keratitis induced by herpes simplex virus type 1 (HSV-1) ocular infection is a leading infectious cause of blindness.
  • Intramuscular Vaccination With the HSV-1(VC2) Live-Attenuated Vaccine Strain Confers Protection Against Viral Ocular Immunopathogenesis Associated With T Cell Intracorneal Infiltration.

European Molecular Diagnostics Market (2021 - 2026): Increasing Burden of Various Bacterial and Viral Epidemics in the Region - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 22, 2021
Biotechnology, Pharmaceutical, Health, Molecule, Agilent Technologies, Laboratory, Adoption, Roche, British Heart Foundation, Infection, The Super Hero Squad Show, USD, Danaher Corporation, United Kingdom, Abbott Laboratories, GBP, Gonorrhea, Heart, Diagnosis, STI, Chlamydia, COVID-19, PCR, Public, Conditional sentence, Genital herpes, Population, HIV, Prevalence, Severe acute respiratory syndrome coronavirus 2, CAGR, Wart, Pharmaceutical industry, Vaccine, Medical device, Fine chemical, Growth

The COVID-19 outbreak is expected to positively impact the European molecular diagnostics market, as it involves the testing of various biological samples.

Key Points: 
  • The COVID-19 outbreak is expected to positively impact the European molecular diagnostics market, as it involves the testing of various biological samples.
  • Factors, such as the increasing burden of various bacterial and viral epidemics in this region, coupled with increasing demand for point-of-care diagnostics and recent advancements in pharmacogenomics, are expected to propel market growth over the forecast period.
  • Thus, the heavy burden of chronic disease is anticipated to increase the adoption of molecular diagnostics in the region.
  • The European molecular diagnostics market is competitive due to the presence of almost all global players in the molecular diagnostics market.

Global Genital Herpes Clinical Trials Review, H2 2021 Market Research Report - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 1, 2021
Infectious Diseases, Pharmaceutical, Health, Clinical Trials, Decision-making, Genital herpes, Trial, Dietary supplement, Pharmaceutical industry

The "Genital Herpes - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Genital Herpes - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • The clinical trial report provides an overview of Genital Herpes Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Genital Herpes.
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.

Hims & Hers Expands Support for Men’s Sexual Wellness With Introduction of Climax Delay Wipes

Retrieved on: 
Tuesday, November 2, 2021
Men, General Health, Health, Specialty, Online Retail, Consumer, Retail, Other Health, Hims & Hers Health, Atomic, SVP, Entrepreneurship, Condom, Genital herpes, Dermatology, Health minister, Pachydactylus labialis, NYSE, Erectile dysfunction, Â, Homs, Reproductive health, Prescription, Time, Premature ejaculation, Mental health, CEO, Man, Solution, Health, Hers, Lubricant, Health insurance, Birth control

Hims & Hers Health, Inc. (Hims & Hers, NYSE: HIMS), the multi-specialty telehealth platform focused on providing modern personalized health and wellness experiences to consumers, today introduced Climax Delay Wipes as a new non-prescription offering within Hims Sexual Health category on forhims.com .

Key Points: 
  • Hims & Hers Health, Inc. (Hims & Hers, NYSE: HIMS), the multi-specialty telehealth platform focused on providing modern personalized health and wellness experiences to consumers, today introduced Climax Delay Wipes as a new non-prescription offering within Hims Sexual Health category on forhims.com .
  • Our new wipes join our line-up of sexual health products like our existing Climax Delay Spray to provide Hims consumers with another option to improve their sexual quality of life by giving them better control in the bedroom and a more delayed climax."
  • In addition to the new Climax Delay Wipes, Hims provides several solutions targeting climax delay including non-prescription Climax Delay Spray as well as access to both daily and as-needed premature ejaculation prescriptions (available if prescribed by a healthcare provider after a telehealth consultation on forhims.com ).
  • For more information about the Climax Delay Wipes, visit https://www.forhims.com/benzocaine-wipes and to learn more about Hims treatment options for premature ejaculation, visit https://www.forhims.com/premature-ejaculation .